Hi there,

This month Democracy Now! is celebrating 28 years on the air. Since our very first broadcast in 1996, Democracy Now! has been committed to bringing you the stories, voices and perspectives you won't hear anywhere else. In these times of war, climate chaos and elections, our reporting has never been more important. Can you donate $10 to keep us going strong? Today a generous donor will DOUBLE your donation, making it twice as valuable. Democracy Now! doesn't accept advertising income, corporate underwriting or government funding. That means we rely on you to make our work possible—and every dollar counts. Please make your gift now. Thank you so much.
-Amy Goodman

Non-commercial news needs your support.

We rely on contributions from you, our viewers and listeners to do our work. If you visit us daily or weekly or even just once a month, now is a great time to make your monthly contribution.

Please do your part today.


NY Drops Indoor Mask Mandate; Pfizer Projects Over $50 Billion in Revenue from COVID Treatments

HeadlineFeb 09, 2022

New York has become the latest Democrat-led state to drop some of its COVID restrictions, lifting its indoor mask-or-vaccine mandate for businesses starting today. Governor Kathy Hochul has not yet announced the future of New York’s schools mask mandate, which is set to expire in two weeks.

Pfizer announced a projected $32 billion in revenue this year from its publicly funded COVID-19 vaccine. That’s just part of Pfizer’s overall projected revenue of around $100 billion in 2022, with another $22 billion coming from the sale of its COVID pill Paxlovid. Pfizer has refused to share its technology with other countries in desperate need of vaccines. Oxfam said in response to Pfizer’s financial report, “Thousands of people in Africa are dying every day from COVID because companies like Pfizer have prioritized profits over saving lives. … No corporations should decide who lives and who dies.”

In other vaccine news, Johnson & Johnson has halted production of its coronavirus vaccine. The Dutch plant making the only usable doses of the shot switched over to production of an experimental vaccine unrelated to COVID. The pause, which started at the end of last year, is expected to last a few months. Many African nations, as well as the COVAX distribution program, rely heavily on J&J’s one-dose vaccine.

The original content of this program is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 United States License. Please attribute legal copies of this work to democracynow.org. Some of the work(s) that this program incorporates, however, may be separately licensed. For further information or additional permissions, contact us.

Non-commercial news needs your support

We rely on contributions from our viewers and listeners to do our work.
Please do your part today.
Make a donation